Please use this identifier to cite or link to this item:
Title: Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Authors: Mifsud, Simon
Schembri, Emma Louise
Montebello, Annalisa
Gruppetta, Mark
Keywords: Non-insulin-dependent diabetes -- Complications
Hypoglycemic agents
Hyperglycemia -- Treatment
Issue Date: 2020-10
Publisher: University of Malta. Medical School
Citation: Mifsud, S., Schembri, E. L., Montebello, A., & Gruppetta, M. (2020). Sodium-glucose co-transporter 2 (SGLT2) inhibitors. Malta Medical Journal, 32(2), 77-90.
Abstract: Type 2 diabetes mellitus is a progressive metabolic disorder. Marked hyperglycaemia leads to serious vascular complications. Hence, addressing this modifiable risk factor is of paramount importance. Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a relatively new class of antidiabetic agents. They offer an intermediate glucose-lowering effect and through other pleiotropic effects provide cardiac and renal benefits. This review focuses on the mechanism of action, benefits and adverse effects of SGLT2 inhibitors. The authors also delineate the ideal type 2 diabetic candidate to receive SGLT2 inhibitors. This is critical as SGLT2 inhibitors should not be used in a ‘one-size-fits-all approach’ but their use should be individualized based on certain patient characteristics. This patient-centred approach aims at maximizing the benefits and reduce the risks associated with SGLT2 inhibitors.
Appears in Collections:MMJ, Volume 32, Issue 2
MMJ, Volume 32, Issue 2
Scholarly Works - FacM&SMed

Files in This Item:
File Description SizeFormat 
MMJ32(2)A7.pdf477.96 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.